Core Viewpoint - Viatris Inc. has filed applications for the approval of Effexor SR Capsules (venlafaxine hydrochloride) to treat generalized anxiety disorder (GAD) in Japan, addressing a significant unmet medical need as no other treatment is currently approved for this indication in the country [1][2]. Company Overview - Viatris Inc. is a global healthcare company that aims to bridge the gap between generics and brand-name medications, providing access to high-quality medicines for approximately 1 billion patients annually [7][8]. Clinical Study Results - A Phase 3 study (Study B2411367) demonstrated the superiority of venlafaxine's anxiolytic effects compared to placebo at 8 weeks, achieving statistical significance (p-value=0.012) and meeting all seven secondary efficacy endpoints [2]. - The results from this study, along with findings from a long-term extension study, were included in the applications submitted to the Ministry of Health, Labor and Welfare (MHLW) [2]. Market Context - In Japan, the World Health Organization reports that 2.6% of the population will experience GAD in their lifetime, with a recent study indicating a probable prevalence of 7.6%, suggesting that GAD may be significantly underdiagnosed [6][5]. - Outside Japan, Effexor is already approved for GAD in over 80 countries, while it is currently approved in Japan only for major depressive disorder [3].